

Amniotics presents promising PulmoStem™ data at ISHLT 2022

Amniotics AB (publ) (Nasdaq Stockholm: AMNI) today announced that an abstract with promising pre-clinical data on the effect of PulmoStem™ in lung transplantation has been accepted for an oral presentation at the International Society for Heart and Lung Transplantation (ISHLT) 42nd Annual Meeting & Scientific Sessions, which will be held on the April 27-30th in Boston.

The oral presentation at ISHLT2022 will be given by Dr. A. Niroomand, from the Lindstedt group at Lund University and Skåne University Hospital in Sweden and include new pre-clinical data on Amniotics biological therapy PulmoStem™. The effect of PulmoStem™ has been tested in a pre-clinical lung transplantation model using ARDS-damaged donor lungs, by Professor Sandra Lindstedt and her group at Lund University and Skåne University Hospital in Sweden.

"We are proud that these promising data on PulmoStem™ has been accepted for an oral presentation at ISHLT 2022. Lung transplantation has become an increasingly common procedure but is lagging behind other transplantations in terms of survival. The data being presented on PulmoStem™ at this meeting shows Amniotics commitment to help patients suffering from lung disease and to better understand how to advance the medical procedures in this space," says CEO Kåre Engkilde

Lung transplantation is currently the only effective treatment for patients with end stage lung disease. However, most potential donor lungs are considered unsuitable for transplantation. Once a suitable donor lung is found, a transplantation can be made. Thereafter the patient undergoes a surgical procedure with the risk of developing PGD, which is a severe lung injury that occurs within the first 72 hours of lung transplantation and is the most common cause of early mortality and co-morbidity.

The oral presentation at ISHLT 2022 will be part of a session presenting novel translational research which advances the understanding of acute lung injury and Chronic Lung Allograft Dysfunction (CLAD) and highlights potential interventions for the salvage of un-transplantable donor lungs.

Presentation details

Session 06: Translational Insights into Lung Transplant Complications and Care

Presentation title: Mesenchymal Stromal Cell Therapy Regenerates Rejected Donor Lungs and Reduces Primary Graft Dysfunction Following Lung Transplantation

Presented by: A. Niroomand

Date: April 27th at 11:00-11:15

For further information, please contact:

Kåre Engkilde
CEO, Amniotics AB
Phone: +46 (0) 723 27 85 20
Email: ke@amniotics.com

Johny Humaloja
CFO, Amniotics AB
Phone: +46 (0) 73 506 6856
Email: jh@amniotics.com

About Amniotics

Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics has also an, by Läkemedelsverket (Swedish MPA), approved Good Manufacturing Practice (GMP) facility to produce Advanced Therapy Medicinal Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now moving into clinical trials with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs.

Amniotics (publ) has it's headquarter in Lund, Sweden.

Amniotics Certified Adviser on First North is Redeye AB, certifiedadviser@redeye.se, telephone: +46 (0) 8 121 576 90.

The company is listed at Nasdaq First North Growth Market in Stockholm.

Learn more at www.amniotics.com.

Attachments

[Amniotics presents promising PulmoStem™ data at ISHLT 2022](#)